These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 3591312)
41. The effect of bismuth subsalicylate on the histologic gastritis seen with Campylobacter pylori: a placebo-controlled, randomized study. Lanza FL; Skoglund ML; Rack MF; Yardley JH Am J Gastroenterol; 1989 Sep; 84(9):1060-4. PubMed ID: 2773899 [TBL] [Abstract][Full Text] [Related]
42. Comparison of automated microbroth dilution and agar dilution for antimicrobial susceptibility of Campylobacter jejuni isolated from dairy sources. Halbert LW; Kaneene JB; Mansfield LS; Ruegg PL; Warnick LD; Wells SJ; Fossler CP; Campbell AM; Geiger-Zwald AM J Antimicrob Chemother; 2005 Oct; 56(4):686-91. PubMed ID: 16131517 [TBL] [Abstract][Full Text] [Related]
44. Sucralfate and other non-antisecretory agents in the treatment of peptic ulcer disease. May B Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():113-6. PubMed ID: 2657280 [TBL] [Abstract][Full Text] [Related]
45. Treatment of Campylobacter pylori-associated antral gastritis in children with bismuth subsalicylate and ampicillin. Drumm B; Sherman P; Chiasson D; Karmali M; Cutz E J Pediatr; 1988 Nov; 113(5):908-12. PubMed ID: 3183851 [TBL] [Abstract][Full Text] [Related]
46. In vitro susceptibility of Campylobacter jejuni and Campylobacter coli isolated in Austria to erythromycin and ciprofloxacin. Hirschl AM; Wolf D; Berger J; Rotter ML Zentralbl Bakteriol; 1990 Apr; 272(4):443-7. PubMed ID: 2360966 [TBL] [Abstract][Full Text] [Related]
47. Stress ulcer prophylaxis and ventilation pneumonia: prevention by antibacterial cytoprotective agents? Daschner F; Kappstein I; Engels I; Reuschenbach K; Pfisterer J; Krieg N; Vogel W Infect Control Hosp Epidemiol; 1988 Feb; 9(2):59-65. PubMed ID: 3343501 [TBL] [Abstract][Full Text] [Related]
48. Antimicrobial activity of bismuth subsalicylate on Clostridium difficile, Escherichia coli O157:H7, norovirus, and other common enteric pathogens. Pitz AM; Park GW; Lee D; Boissy YL; Vinjé J Gut Microbes; 2015; 6(2):93-100. PubMed ID: 25901890 [TBL] [Abstract][Full Text] [Related]
49. In vitro susceptibilities of Campylobacter-like organisms to twenty antimicrobial agents. Flores BM; Fennell CL; Holmes KK; Stamm WE Antimicrob Agents Chemother; 1985 Aug; 28(2):188-91. PubMed ID: 3834828 [TBL] [Abstract][Full Text] [Related]
51. Susceptibility of Campylobacter pyloridis to three macrolide antibiotics (erythromycin, roxithromycin [RU 28965], and CP 62,993) and rifampin. Czinn S; Carr H; Aronoff S Antimicrob Agents Chemother; 1986 Aug; 30(2):328-9. PubMed ID: 3767346 [TBL] [Abstract][Full Text] [Related]
52. Comparative antimicrobial activity of gatifloxacin tested against Campylobacter jejuni including fluoroquinolone-resistant clinical isolates. Hayward CL; Erwin ME; Barrett MS; Jones RN Diagn Microbiol Infect Dis; 1999 Jun; 34(2):99-102. PubMed ID: 10354858 [TBL] [Abstract][Full Text] [Related]
53. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. Goodwin CS; Marshall BJ; Blincow ED; Wilson DH; Blackbourn S; Phillips M J Clin Pathol; 1988 Feb; 41(2):207-10. PubMed ID: 3280609 [TBL] [Abstract][Full Text] [Related]
54. Campylobacter strains isolated from slaughtered chickens: their sensitivity to antibiotics and resistance to erythromycin. Marjai E; Adám MM; Horváth Z; Kajáry I; Kováts Z Acta Microbiol Hung; 1985; 32(2):125-31. PubMed ID: 4061047 [TBL] [Abstract][Full Text] [Related]
55. Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. McNulty CA; Gearty JC; Crump B; Davis M; Donovan IA; Melikian V; Lister DM; Wise R Br Med J (Clin Res Ed); 1986 Sep; 293(6548):645-9. PubMed ID: 3092967 [TBL] [Abstract][Full Text] [Related]
56. Newer drugs in the treatment of peptic ulcer. Tandon BN Trop Gastroenterol; 1985; 6(4):188-92. PubMed ID: 3913076 [No Abstract] [Full Text] [Related]
57. Reduction of capsular polysaccharide and potentiation of aminoglycoside inhibition in gram-negative bacteria by bismuth subsalicylate. Domenico P; Landolphi DR; Cunha BA J Antimicrob Chemother; 1991 Dec; 28(6):801-10. PubMed ID: 1816178 [TBL] [Abstract][Full Text] [Related]
58. Cost analysis and antimicrobial susceptibility testing comparing the E test and the agar dilution method in Campylobacter jejuni and Campylobacter coli. Valdivieso-García A; Imgrund R; Deckert A; Varughese BM; Harris K; Bunimov N; Reid-Smith R; McEwen S Diagn Microbiol Infect Dis; 2009 Oct; 65(2):168-74. PubMed ID: 19748428 [TBL] [Abstract][Full Text] [Related]
59. Gastric mucosa protection and prostaglandin E2 generation in rats by colloidal bismuth subcitrate (DE-NOL). Hall DW; van den Hoven WE Arch Int Pharmacodyn Ther; 1987 Apr; 286(2):308-19. PubMed ID: 3473983 [TBL] [Abstract][Full Text] [Related]
60. In vitro activities of new oral beta-lactams and macrolides against Campylobacter pylori. García-Rodríguez JA; García Sánchez JE; García García MI; García Sánchez E; Muñoz Bellido JL Antimicrob Agents Chemother; 1989 Sep; 33(9):1650-1. PubMed ID: 2817868 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]